Led · Series E · Apr 2018

Innovent Biologics develops complex, affordable biopharmaceutical products targeting cancer, ophthalmology, autoimmune disorders and cardiovascular diseases. The company has built a large-scale GMP-compliant manufacturing base meeting CFDA, FDA and EMA standards. Its pipeline comprises 16 molecules in research, seven in clinical development (four in Phase III) and one with a BLA submitted to the CFDA. Innovent plans to use new funding to accelerate and expand clinical programs and to build a commercial team. The company was founded in August 2011 by Dr. Michael Yu and operates from Suzhou. It has received national research recognitions and grants for multiple molecules.

Led · Series E · Apr 2018

Innovent Biologics is a Hong Kong-based biotech that develops and manufactures affordable complex biopharmaceutical products. Founded in August 2011 by Dr. Michael Yu, the company has built a portfolio targeting cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. It currently has 16 molecules in research, seven in clinical development, four in Phase III and one with a BLA submitted to the CFDA. Five molecules have been selected under the national mega innovative program and one received a precision medicine research grant under China's National Key R&D Plan. Innovent has a large-scale manufacturing base compliant with CFDA, FDA and EMA GMP standards. The company intends to use the funds to speed up and expand clinical programs and to build a commercial team. Innovent Biologics is a Shanghai, China–based biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of biologics. Founded in August 2011 by Michael Yu, Ph.D., the company has built a portfolio of 12 product candidates targeting cancer, autoimmune disorders, ophthalmology and cardiovascular diseases. Innovent has filed eight IND applications and has four products in clinical development, three of which are in phase 3 trials. The company operates under rigorous cGMP requirements and is expanding its manufacturing capacity. It intends to use new funding to continue development of innovative biopharmaceutical products, expand manufacturing, and support ongoing operations. Innovent Biologics is a Shanghai-based biopharmaceutical company dedicated to the development and manufacturing of complex biologics. Led by co-founder, president and CEO Michael Yu, the company is advancing an internal pipeline of eight antibody products, including one approved IND and four additional filed applications. Innovent aims to market its portfolio in the Chinese market and internationally while meeting EMEA and FDA/cGMP standards. Its strategy combines advancing proprietary biologic drugs with establishing in- and out-licensing agreements with global pharmaceutical and biotech companies. The company plans to use newly raised funds to advance its pipeline and grow operations. Innovent raised capital to support these plans and expand its development and manufacturing activities.

Participated · Equity · Aug 2016

Gojek operates ride-hailing and payments services in Indonesia and has expanded into food delivery and other digital services. The company is working to seal a proposed merger with e-commerce platform Tokopedia to create a new entity called GoTo in an $18 billion deal, according to media reports. Gojek has raised over $3.45 billion to date from investors including Google, Facebook, PayPal, Visa, and Tencent. It maintains a strategic partnership with Telkomsel dating to 2018 that includes subsidizing mobile data costs for driver partners and integrations such as Telkomsel MyAds with GoBiz and onboarding MSME partners via the DigiPOS Aja! application. The firms also co-market gaming services through Telkomsel’s Dunia Games and GoPay in collaboration with Tencent. Telkomsel, which has more than 170 million subscribers, said the investment will open opportunities to scale digital services and innovations developed by homegrown companies. Gojek began as a ride-hailing service and has grown into a multi-service platform that includes digital payments and food delivery. The company serves about 170 million users in Indonesia. Gojek has raised over $3 billion to date and was valued at about $10 billion earlier this year. It has been lossmaking and competes directly with rival Grab. Gojek and telecom operator Telkomsel have an ongoing commercial relationship dating back to 2018 to subsidize driver mobile data usage. The firms say they will explore a broad range of collaboration opportunities to reach millions more Indonesians and deepen digital-economy adoption. Gojek operates ride-hailing, meal delivery, and payments services across Southeast Asia. The company announced a $1.2 billion funding round and has now raised nearly $3 billion in total. Investors in the latest round were not disclosed, although existing backers include Google, Tencent, and Temasek. Leadership is held by co-CEOs Andre Soelistyo and Kevin Aluwi after founder Nadiem Makarim left to become Indonesia’s education and culture minister. Gojek said it will use the new funding to expand operations and that it is engaged in ongoing conversations with potential partners. The company faces competition from Grab and has been the subject of merger-talk rumors; there were also unconfirmed reports of interest from Amazon. Gojek is an Indonesian ride-hailing and multi-service company that offers a range of on-demand services. The company has launched a new video streaming offering. Gojek plans to add Japanese content to that streaming service as part of a partnership with investors. The immediate financial development is a planned investment of about $50 million from the state-backed Cool Japan Fund. The investment is also intended to promote Japanese cuisine through Gojek’s platform. No other financial metrics or user numbers are provided in the article. Go-Jek operates a ride-hailing and on-demand services platform and is expanding its core transport offering across Southeast Asia. The company is raising a Series F round and pulled in $100 million from Astra, an existing investor. Go-Jek is aiming to bring in at least $2 billion in the round and has closed around half of that capital. Astra's investment includes a strategic joint venture to equip Go-Jek's cars with Astra's fleet management system, with a rollout starting with "thousands" of Go-Car drivers. The capital is being raised to expand Go-Jek's services regionally; the company recently launched its Thailand-based Get business, has expanded to Vietnam and Singapore, and is primed to offer services in the Philippines soon. The company is Indonesian and competing for regional market share.

Participated · Equity · Jul 2015

Didi Autonomous Driving is the self-driving arm of ride-hailing giant Didi that focuses on Level-4 autonomous vehicle technology and related AI systems. The company has spent nearly a decade building expertise in artificial intelligence, mass production, and large-scale operations for autonomous mobility. In 2025 it began full-scenario, fully unmanned road testing in Beijing and Guangzhou, with vehicles operating smoothly during rush hours, late nights, and heavy rain. A next-generation pre-installed autonomous vehicle, co-developed with GAC Aion, is scheduled for delivery by late 2025, after which Didi plans demonstration applications in both cities. The firm believes L4 autonomy will dramatically improve transportation safety, efficiency, and user experience while opening new employment opportunities. Fresh capital from its recent Series D round will be channelled into AI R&D and the accelerated rollout of L4 services. No revenue, user, or other operating metrics were disclosed in the announcement.